A Study of BAX 930 in Children Teenagers and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

  • End date
    Jan 1, 2024
  • participants needed
  • sponsor
    Baxalta now part of Shire
Updated on 19 September 2021


Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed underneath the skin forming purple bruises or purpura, or from the surface of the skin. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them leading to lower than normal number of red blood cells.

A lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in blood clotting, causes TTP. The enzyme breaks up another blood protein called von Willebrand factor that clumps together with platelets to form blood clots. Some people are born with this condition, others get the condition during their life. Many people who born with TTP experience frequent flareups that need to be treated right away. If not treated It can be fatal or cause lasting damage, such as brain damage or a stroke. BAX 930 is a medicine that replaces ADAMTS13 and can prevent or control TTP flareups, called TTP episodes.

The main aim of this study is to compare the number of TTP episodes in people born with severe TTP when they treated with BAX 930 versus when they are treated with the standard treatment. Treatment will be given in 2 ways:

  • BAX 930 or standard treatment given to prevent TTP episodes from happening.
  • BAX 930 or standard treatment given to control an acute TTP episode when it happens, according to the clinic's standard practice.

Both BAX 930 and standard treatment are given slowly through a vein (infusion).

At the first visit, the study doctor will check if you can participate in the study. If you are eligible and enter the study, you will follow an assigned schedule and either start with BAX 930 (Period 1) and then switch to standard treatment (Period 2) or start with standard treatment (Period 1) and then switch to BAX 930 (Period 2). Everyone will be treated with BAX 930 again for Period 3. Each Period will last approximately 6 months.

If you enter the study to control an acute TTP episode, you will follow a schedule receiving either BAX 930 or standard care to treat your acute TTP episode. Once the acute TTP episode has gotten better, you can decide to continue in the study and be given treatment to prevent TTP episodes from happening, following the schedule above.

Another study's aim is to assess side effects from treatment with BAX 930 and standard treatment. To do that, the study doctor will ask you questions about your health at each study visit.

The study doctors will also check how long BAX 930 stays in the blood of the participants, over time. They will do this from blood samples taken after participants receive their specific infusions of BAX 930. This will happen at different times during the study.

1 month after all treatment has been completed, participants will visit the clinic for a final check-up.

Treatment Standard of Care, BAX930
Clinical Study IdentifierNCT03393975
SponsorBaxalta now part of Shire
Last Modified on19 September 2021


Yes No Not Sure

Inclusion Criteria

Participant or legally authorized representative has provided signed informed consent greater than or equal to (>=) 18 years of age and/or assent form (signed by legal representative if participants is less than (<) 18 years of age)
Participant is 0 to 70 years of age, inclusive, at the time of screening. (Participants < 18 years of age will be enrolled only after at least 5 adults (>= 18 years of age) each have at least 10 exposures with BAX 930 and reviewed by the Data Monitoring Committee (DMC). In France, no participants younger than 18 years of age will be enrolled into the study before the first adult participant has been treated with BAX 930 for a minimum of 6 months
Participant has a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as
Confirmed by molecular genetic testing, documented in participant history or at screening, and
A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity < 10 percent (%) as measured by the fluorescent resonance energy transfer- von Willebrand factor73 (FRETS-VWF73) assay, documented in participant history or at screening (participants currently receiving standard of care (SoC) prophylactic therapy may exceed 10% ADAMTS13 activity at screening)
Note: Participants currently receiving prophylactic therapy will be screened
immediately prior to their usual prophylactic infusion
Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count < 100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>2)upper limit of normal (ULN)) at screening. (Prophylactic cohort only)
Participant is currently on a prophylactic dosing regimen or has a documented history of at least 1 TTP event and an ability to tolerate SoC prophylactic dosing (prophylactic cohort only)
Participants >= 16 years of age must have a Karnofsky score >= 70% and participants < 16 years of age must have a Lansky score >= 80%
Participant is hepatitis C virus (HCV)-negative as confirmed by antibody or polymerase chain reaction testing OR HCV-positive if their disease is chronic but stable
If female of childbearing potential, participant presents with a negative blood or urine pregnancy test, confirmed no more than 7 days before the first administration, and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing
Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered
Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria

Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including acquired TTP
Participant has known hypersensitivity to hamster proteins
Participant has experienced an acute TTP episode less than 30 days prior to screening (prophylactic cohort only)
Participant has a medical history or presence of a functional ADAMTS13 inhibitor at screening
Participant has a medical history of genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus (HIV)-positive with an absolute cluster of differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving chronic immunosuppressive drugs
Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4)
Participant with end stage renal disease requiring chronic dialysis
Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following
Serum alanine aminotransferase (ALT) >= 2 upper limit of normal (ULN)
Severe hypoalbuminemia < 24 gram per liter (g/L)
Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices)
In the opinion of the investigator, the participant has another clinically significant concomitant disease that may pose additional risks for the participant
Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of corticosteroids in conjunction with administration of fresh frozen plasma (FFP) to prevent allergic manifestations is permitted
Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylaxis cohort only)
Participant is receiving or anticipates receiving another investigational drug and/or interventional drug within 30 days before enrollment
Participant has a history of drug and/or alcohol abuse within the last 2 years
Participant has a progressive fatal disease and/or life expectancy of less than 3 months
Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude
Participant is a family member or employee of the sponsor or investigator
If female, participant is pregnant or lactating at the time of enrollment
Any contraindication to SoC medicinal product(s) as per local prescribing information
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note